1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
DongKook Life Science

DongKook Life Science

303810.KQ
DongKook Life ScienceKR flagKOSDAQ
2,470.00
KRW
+50.00
- -
79.00BMarket Cap
DongKook Life Science
303810.KQ
(KOSDAQ)

Recent

price

2,470.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
30,144.72
40,629.1
44,047.64
48,950.28
45,859.21
47,896.26
5,363.9
2,348.9
4,139.92
3,010.34
Revenue per Share
2,112.5
2,772
2,804.5
1,990
2,616.5
1,893.5
186
40
275
204.34
Basic EPS, GAAP
2,979.2
1,870.61
471.79
-6,796.92
-13,439.34
-9,064.87
-419.53
115.02
-166.97
-29.16
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
5,238.93
5,517.46
8,187.11
10,424.78
13,040.74
14,933.51
1,678.49
733.86
1,869.71
1,434.45
Book Value per Share
21,894.47
19,474.09
22,357.34
24,005.05
24,430.91
26,426.02
2,801.96
1,772.19
4,006.96
3,014.85
Tangible Book Value per Share
2
2
2
2
2
2
22
56
31
43
Basic Weighted Avg Shares
50,450
87,707
98,617
109,583
102,668
107,234
120,161
131,816
130,344
128,377
Sales/Revenue/Turnover
7.49
8.15
7.05
7.69
6.62
5.81
7.1
9.04
10.01
10.42
Operating Margin (%)
467
1,343
2,014
2,089
2,385
2,461
3,283
5,782
6,411
6,492
Depreciation Expense
3,535
5,984
6,279
4,455
5,858
4,239
4,167
2,245
8,658
8,714
Net Income, GAAP
- -
23.78
14.67
33.72
8.94
19.72
13.73
52.77
20.04
19.48
Effective Tax Rate (%)
7.01
6.82
6.37
4.07
5.71
3.95
3.47
1.7
6.64
6.79
Profit Margin (%)
30,477
35,021
36,064
21,402
2,618
10,024
11,514
52,776
57,888
59,875
Working Capital
360
120
64
89
10,205
25,237
18,788
22,509
5,424
5,509
LT Debt
36,885
42,240
50,139
54,451
60,469
65,129
68,704
105,224
131,366
133,637
Total Equity
- -
11.66
11.48
9.75
8.77
5.33
6.7
4.26
6.55
6.38
Return on Invested Capital (%)
- -
35.89
31.94
20.76
19.97
11.18
10.56
7.01
12.67
11.72
Return on Capital (%)
- -
57.88
41.53
21.38
22.3
13.54
11.73
5.7
17.31
16.5
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
34,131
33,559
33,765
LT Borrowings
3,786
3,687
3,588
LT Finance Leases
335
1,737
1,922
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
32
32
Market Capitalization
209,744
190,251
144,995

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
130,555
138,560
144,389
Cash, Cash Equivalents & STI
7,929
7,254
8,182
Accounts Receivable, Net
85,059
90,658
97,057
Inventories
31,812
35,230
33,516
Total Current Liabilities
72,570
80,672
84,514
Payables & Accruals
- -
- -
- -
ST Debt
34,131
33,559
33,765
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
20.45%
24.84%
Free Cash Flow
- -
-67.73%
-181.45%
Net Income, GAAP
- -
48.35%
285.71%
Sales/Revenue/Turnover
- -
3.75%
-1.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
33,567
34,044
32,410
31,795
131,816
2025
35,050
34,889
29,438
30,967
130,344
2026
33,084
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
30.5
-29
67
- -
40
2025
37.5
44.58
75.39
- -
275
2026
72.09
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Shanghai Conant Optical Co., Ltd. (2276.HK)
Terumo Corporation (4543.T)
Paramount Bed Holdings Co., Ltd. (PBHDF)
Elekta AB (publ) (EKTAF)
Perfect Medical Industry Co., Ltd. (6543.TWO)
Shanghai Kindly Enterprise Development Group Co.,LTD. (603987.SS)
Business
DongKook Life Science Co., Ltd. is a specialized pharmaceutical company engaged in the development, manufacturing, and sale of diagnostic pharmaceutical products and medical devices. The company's core offerings include contrast media for diagnostic imaging such as X-ray contrast media, nuclear magnetic resonance (MRI) contrast media, iodized oil contrast media, and related diagnostic pharmaceutical products. It also manufactures and distributes active pharmaceutical ingredients (APIs) including Cilastatin Sodium, Gadobutrol, Iopamidol, DOTA, and others, alongside medical and diagnostic equipment. DongKook Life Science operates globally, supplying its products to 17 countries. Founded in 2017 and headquartered in Seoul, South Korea, DongKook Life Science applies advanced technologies in desalting, purification, and sterilization to ensure high-quality and innovative products for the diagnostic medicine market. The company targets healthcare providers and diagnostic centers worldwide. Recent major developments include the company’s successful ₩18 billion (approximately USD 12.5 million) initial public offering (IPO) on the Korea Exchange in 2025, marking it as South Korea's first med-tech listing of the year. Furthermore, DongKook Life Science signed a strategic partnership memorandum of understanding (MOU) with China's Zhejiang Tianyu to enhance its market presence and collaborate on product development and distribution. These moves reflect the company’s strategic expansion and commitment to strengthening its global footprint in the diagnostic pharmaceutical and medical device sectors.